| Haemolytic uraemic syndrome associated with gemcitabine. | |
| | |
MedLine Citation:
|
PMID: 20466623 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Haemolytic uraemic syndrome (HUS) is a rare thromboembolic complication observed in patients with cancer. It is characterised by the clinical triad of acute renal failure, microangiopathic haemolytic anaemia and thrombocytopaenia. It may be associated with a variety of aetiologies, including chemotherapeutic agents such as mitomycin, cisplatin, bleomycin, 5-fluorouracil and, most recently, gemcitabine. We report a 70-year-old patient treated with gemcitabine who developed haemolytic uraemic syndrome. |
| | |
Authors:
|
Irene Moya-Horno; Rosa Querol Niñerola; Teresa Bonfill Abella; Elsa Dalmau Pórtulas; Enrique Gallardo-Díaz; Eugeni Saigí Grau; Carles Pericay Pijaume |
Related Documents
:
|
8580023 - Acquired glomerulocystic kidney disease following haemolytic-uraemic syndrome. 17335633 - Clinical surveillance of thrombotic microangiopathies in scotland, 2003-2005. 7554353 - Haspeslagh syndrome without severe mental retardation and pterygia? |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Volume: 12 ISSN: 1699-3055 ISO Abbreviation: Clin Transl Oncol Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-14 Completed Date: 2010-08-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101247119 Medline TA: Clin Transl Oncol Country: Spain |
Other Details:
|
Languages: eng Pagination: 381-3 Citation Subset: IM |
Affiliation:
|
Medical Oncology Service, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use Carboplatin / administration & dosage Carcinoma / drug therapy, pathology Deoxycytidine / administration & dosage, adverse effects, analogs & derivatives* Hemolytic-Uremic Syndrome / chemically induced* Humans Male Urinary Bladder Neoplasms / drug therapy, pathology Urothelium / drug effects, pathology |
| Chemical | |
Reg. No./Substance:
|
103882-84-4/gemcitabine; 41575-94-4/Carboplatin; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Use of an electron spoiler for radiation treatment of surface skin diseases.
Next Document: Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.